Trusting relationships between pregnant and postpartum women with substance use
disorders (SUDs) and maternity nurses can improve health outcomes for women and their …

Introduction: Mothers who use substances can play a key role in the treatment and care of
their infants. However, challenges exist to engaging these mothers in the care of their infant …

Neonatal abstinence syndrome (NAS) is a constellation of signs involving the central and
autonomic nervous, respiratory, and gastrointestinal systems, that typically appear in the first …

Se revisan las consecuencias del uso de sustancias y la seguridad de los fármacos
indicados para el tratamiento del trastorno por uso de alcohol, nicotina y opioides durante el …

Substance use disorder is common and has significant implications for both mothers and
their neonates with increased risk of morbidity and mortality. Through education and …

Long-term medication treatment has been demonstrated to be the most effective treatment
for opioid use disorder. This chapter covers the treatment of opioid withdrawal and the use of …

Background Breastfeeding impacts multiple health outcomes but less than 50% of UK
women breastfeed at 8 weeks. Women with long-term conditions face additional challenges …

The postpartum period is a critical transition for women with substance use disorders (SUD)
and is characterized by significant physiologic, social and emotional change. Offen referred …

Methadone maintenance treatment (MMT) is recommended as the standard of care for
opioid-dependent pregnant women. Compared to heroin use in pregnancy, MMT is …

Neonatal abstinence syndrome (NAS) is a term used to describe postnatal withdrawal
syndrome that occurs in infants as a result of fetal exposure to drugs. Signs of NAS include …